Navigation Links
Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohn's Disease
Date:9/16/2010

SAN DIEGO, Sept. 16 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement.  The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia®, Humira® and Remicade® utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

Under the terms of the exclusive agreement, Tarrot and Prometheus will jointly fund and share technology for research and development activities. Tarrot will receive additional payments upon the achievement of certain development milestones and a royalty based upon product revenues.  Prometheus will receive rights to intellectual property as well as the diagnostic tests that are jointly developed.

"We are pleased to collaborate with Tarrot on this exciting technology. This collaboration enhances Prometheus' continued expansion of our business model, focusing on personalized medicine in gastroenterology," said Joseph M. Limber, Prometheus' President and Chief Executive Officer. "The ability to identify and stratify patients for optimization of therapy, including certain biologic therapies used to treat Crohn's disease and rheumatoid arthritis, is extremely important in patient care."

"Tarrot brings strong clinical capabilities to this collaboration and access to Cedars-Sinai Medical Center, which treats nearly 4,000 patients with Inflammatory Bowel Disease annually," said Richard Katzman, Chief Executive Officer of Tarrot.  "We believe our strong technical expertise in the areas of genetic testing, data analysis and modeling will be utilized to create new discoveries in this area of pharmacogenomics.  We are pleased to be working with Prometheus, a partner with a proven history of developing and commercializing novel, proprietary diagnostics to improve physician's ability to personalize patient care."

About Tarrot

Established in 2008, Tarrot is a business unit of Cedars-Sinai Medical Center.  Tarrot's vision is to deliver the promise of personalized prognosis, diagnosis, and treatment to people with Inflammatory Bowel Disease. The company utilizes its proprietary Subject Stratification and Clustering Engine to: (1) Predict disease severity and progression in defined subject groups; (2) Work with companies to design and implement enhanced Phase 2A, 2B, and Phase 3 patient specific clinical trials, and; (3) Identify new drug targets through our deep insights into mechanisms which drive IBD.  Tarrot's facilities are located in Los Angeles, California.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.

Cimzia® is a registered trademark of UCB Pharma, S.A. Humira® is a registered trademark of Abbott Laboratories and Abbott Biotechnology Ltd.  Remicade® is a registered trademark of Centocor Ortho Biotech Inc.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
2. Prometheus Receives New York State Approval for PROMETHEUS(R) IBS Diagnostic, First Blood Test for Irritable Bowel Syndrome
3. Prometheus Research Signs 3-Year Contract With Simons Foundation to Expand HTSQL Informatics System for Autism Research
4. Prometheus Research Awarded National Science Foundation Grant for Easy to Use, Web-Enabled Database Software
5. DNA Genotek Sample Collection Kit Selected by Prometheus for MyCeliacID™ Genetic Test
6. Prometheus Research Informatics Technology Enables Multiple Presentations at IMFAR
7. AIT Laboratories Expands Pharma Services
8. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
10. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
11. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):